BioPharma « Terug naar discussie overzicht

ampio pharma + 20%

5 Posts

Omlaag ↓

[verwijderd] 6 december 2016 16:55

Ik weet niet waarom die zo omhoog schiet, geen nieuws te vinden maar schiet dus zomaar even van slot gisteren op 0,80 omhoog en heeft 2x de 1 dollar aangetikt vandaag.

ampiopharma.com/

[verwijderd] 6 december 2016 17:00

www.desotoedge.com/stocks/ampio-pharm...

Ampio Pharmaceuticals, Inc. (AMPE) Reviewed By Analysts
By Ashley Brown / in Stocks / on Tuesday, 06 Dec 2016 11:49 AM / 0 Comments
Stock market analysts watching Ampio Pharmaceuticals, Inc. (AMPE) have recently changed their ratings on the stock. The latest reports which are outstanding on Tuesday 6th of December state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Latest stock market analyst ratings:

08/22/2014 – Ampio Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Jefferies. They now have a USD 5 price target on the stock.

08/21/2014 – Ampio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Aegis Capital.

05/08/2014 – Citigroup began new coverage on Ampio Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 21 price target on the stock.

Ampio Pharmaceuticals, Inc. has a 50 day moving average of 0.72 and a 200 day moving average of 1.42. The stock’s market capitalization is 45.97M, it has a 52-week low of 0.59 and a 52-week high of 4.32.

The share price of the company (AMPE) was up +4.39% during the last trading session, with a high of 0.82 and the volume of Ampio Pharmaceuticals, Inc. shares traded was 318414.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

[verwijderd] 6 december 2016 17:08

Ook de 1,048 aangetikt ruim 25%

[verwijderd] 21 september 2020 14:17

AMPE trial results

10 SARS-CoV-2 patients were suffering severe oxygen shortage

5 patients treated with Ampion were all cured and went home

5 patients treated with Remdesivir and SOC, 1 Died, 1 still in hospital, 3 went home

Ampion clearly did 40% better.

[verwijderd] 21 september 2020 14:25

ampalizer.info/

5 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 861,09 -4,27 -0,49% 13:48


Germany40^	17.729,00	-0,61%
BEL 20	3.814,45	-0,32%
Europe50^	4.920,38	-0,33%
US30^	37.719,08	-0,77%
Nasd100^	17.343,78	-1,17%
US500^	5.004,20	-0,89%
Japan225^	37.455,98	-1,44%
Gold spot	2.379,68	+0,01%
EUR/USD	1,0653	+0,09%
WTI	81,64	-0,54%